Conference item icon

Conference item

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials

Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
ORCID:
0000-0002-4756-663X
Publisher:
BMJ Publishing Group
Host title:
Annals of the Rheumatic Diseases
Journal:
Annals of the Rheumatic Diseases More from this journal
Volume:
77
Issue:
Suppl 2
Pages:
375
Publication date:
2018-06-12
Acceptance date:
2018-03-29
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Pubs id:
pubs:1007923
UUID:
uuid:63c3b580-1277-4c78-a288-76e932704f7c
Local pid:
pubs:1007923
Source identifiers:
1007923
Deposit date:
2019-07-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP